Lv4
740 积分 2023-08-29 加入
Now with oligos: antibody–oligonucleotide conjugates are the new drug modality to watch
1个月前
已完结
Anti–PD-1 antibodies recognizing the membrane-proximal region are PD-1 agonists that can down-regulate inflammatory diseases
1个月前
已完结
Tarlatamab in Small-Cell Lung Cancer after Platinum-Based Chemotherapy
3个月前
已完结
Dual-payload ADCs move into first oncology clinical trials
3个月前
已完结
Trastuzumab Deruxtecan or Ramucirumab plus Paclitaxel in Gastric Cancer
3个月前
已完结
Treatment-related adverse events, including fatal toxicities, in patients with solid tumours receiving neoadjuvant and adjuvant immune checkpoint blockade: a systematic review and meta-analysis of randomised controlled trials
3个月前
已完结
Unveiling the molecular and immunological drivers of antibody–drug conjugates in cancer treatment
3个月前
已完结
Overcoming Resistance to Tumor-Targeted and Immune-Targeted Therapies
3个月前
已完结
The current state of the art and future trends in RAS-targeted cancer therapies
3个月前
已完结
Response and Resistance to RAS Inhibition in Cancer
3个月前
已完结
皖公网安备34019202002308
